Prostate cancer
Conditions
Interventions
case series:N/A
Sponsors
Renji Hospital, School of Medicine, Shanghai Jiaotong University
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: 1) 18-75 years old, male; 2) Confirmed prostatic adenocarcinoma by histopathology or cytology; 3) According to the Eau-Eostro-SIOG 2016 guideline, PCa was clinically diagnosed as locally progressive; 4) Had not received new endocrine therapy such as abiraterone or enzalutamide before; 5) Had not received docetaxel or cabatax or combined chemotherapy including docetaxel or cabatax in the past; 6) Had not received PARP inhibitor treatment before; 7) Had not received Xofigo(radium 223 dichloride) treatment before; 8) ECOG score 0-2; 9) Patients have signed informed consent and are capable of following planned study visits, providing blood samples before and after treatment, providing clinical information and cooperating with other study steps.
Exclusion criteria
Exclusion criteria: 1) Histopathological examination of the patient indicated neuroendocrine type/small cell prostate cancer; 2) Having hypertension and poor drug control; 3) Patients with severe cardiopulmonary insufficiency; 4) Abnormal coagulation function, bleeding tendency, or thrombolysis or anticoagulant therapy; 5) any previous diagnosis of any other malignant tumor; 6) Other malignant tumors at the same time; 7) A history of human immunodeficiency virus infection, other acquired or congenital immunodeficiency diseases, or a history of organ transplant, or a history of organ transplant; 8) The clinical information needed for the study cannot be obtained (such as loss of patient follow-up).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Time to recurrence; | — |
Countries
China
Contacts
Public ContactZhu Yinjie
Renji Hospital, School of Medicine, Shanghai Jiaotong University
Outcome results
None listed